Compare Levi Strauss & Co. (LEVI) vs UnitedHealth Group Inc (UNH) Price & Performance

Levi Strauss (LEVI) trades at $24.03, down 1.35% over the past day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.28, exceeding expectations of $0.24, and raised its full-year outlook. Strong fundamentals include a 61.72% gross margin and 9.66% net income margin, supported by a digital strategy driving direct-to-consumer growth. Analyst consensus is overwhelmingly bullish with an 83.33% buy rating and a $28.00 price target, implying significant upside from current levels.

Outlook remains positive given earnings momentum and dividend increases, but risks include tariff pressures and foreign exchange volatility noted in recent reports. The stock's valuation at a P/E of 17.4 appears reasonable relative to profitability, though competitive and macroeconomic headwinds warrant monitoring for sustained growth.

UnitedHealth Group (UNH) trades at $426.09, up 0.64% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $6.38 surpassing expectations of $4.94. Revenue growth remains robust, reaching $447.57 billion in 2025, though net margins have compressed to 2.68%. Recent corporate actions include a $2.32 dividend and ongoing share repurchases, while news highlights operational streamlining like reduced pediatric prior authorizations.

UNH's outlook is positive, driven by aging demographics and tech innovation in healthcare, offering upside to the $467.12 consensus target. Risks include regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish, with 82.69% of analysts rating it a buy, supporting long-term growth prospects amid sector tailwinds.